Policies promote the transformation of the pattern, and investment in the pharmaceutical and biological track welcomes new opportunities

With the implementation of policies such as the normalization of collection and the negotiation of medical insurance in recent years, innovation has become a major trend in the development of the pharmaceutical industry; on the other hand, the epidemic has promoted the synchronous transformation of the pattern of offline retail drugs with the accelerated development of Internet medical treatment. The pharmaceutical sector has shown many new changes, and many subdivisions such as medical beauty and pharmaceutical e-commerce have attracted much attention.

"Left layout, new pattern of medical and biological golden track" roundtable discussion scene

On December 13th, 36Kr "WISE2021 King of new economy capital market summit forum" was held in Shanghai. Huang Yida, senior analyst of 36Kr secondary market, as the host, Sun Yuanyuan, pharmaceutical analyst of Industrial Securities, Li Yizheng, director, deputy general manager and secretary of the board of directors of Bloomage Biologics, and Chen Yang, chief financial officer of 1 Pharmaceutical Network, jointly discussed the roundtable theme of "Left Layout, New Pattern of Pharmaceutical and Biological Golden Track".

The following is a transcript of the statements made at the Roundtable Forum (with abridgements):

Industrial Securities Pharmaceutical Analyst Sun Yuanyuan

"The speed of development of China's innovative pharmaceutical enterprises is amazing"

At present, most companies are still targeting known targets or overseas verified targets when researching and developing, but they have already had differentiated ideas in strategy.

The first is to differentiate indications, China and the United States themselves also have disease differentiation, and the disease spectrum itself is not the same. The second is to choose a less popular target, or the same target but a different technology platform. The third is the original new target.

MRNA technology still has great prospects in the future, and it has greatly improved the efficiency of research and development in vaccine research and development. This technique can also be applied to the treatment of tumors.

There are several difficulties in mRNA, the first of which is the technical level, such as sequence design, patent barriers for delivery systems. The second is large-scale production, the current mRNA production history is relatively small, so the whole technology is not particularly mature. The third is how to solve the problem of normal temperature storage.

Under the encouragement of the policy, the development speed of China's innovative pharmaceutical enterprises is amazing. Some new underlying platforms do not rule out being able to make data out faster or better than globally. The development of the entire innovative drug will show more differentiated and more international characteristics from next year.

Bloomage Biotech Director, Deputy General Manager, Board Secretary Li Yizheng

"The medical aesthetic industry is an industry where explosive products are king"

Now that the state is more and more strict in the supervision of the publicity of cosmetics companies, your publicity effect must be supported by a large number of clinical data. In the short term, more and more companies will pay attention to the underlying research, and the foundation of this industry will become more and more solid.

In the long run, the efficacy of cosmetics will become more and more prominent and targeted. Because the current skin care needs are becoming more and more specialized, many consumers are becoming more and more professional and rational.

In addition, we also attach great importance to the difference between light medical beauty and reshaping. With the development of the concept of consumption, light medical beauty and functional cosmetics themselves are gradually integrated trend, and many medical aesthetic technologies will gradually be used in functional cosmetics in the future.

Medical aesthetics belongs to the concept of consumer medicine, which is also the category of medical treatment, but it is partial to consumer medicine. Consumer medical care is the best track in the medical industry, because it has both high barriers and high research and development investment in medical treatment, as well as huge flexibility and broad space for consumption, we and the market have given a high valuation.

In the future, everyone will invest more research and development funds in the field of medical beauty or life and health. With the investment of large R & D expenses, the iterative upgrading of the industry's products is also very interesting, because this industry is a typical industry where products are king and explosive products are king.

The rest is a domestic alternative. We at Bloomage Bio supplies 60% of the world's pharmaceutical grade hyaluronic acid raw materials, but we only account for 5%-6% of the market share of mid-range products in China, and 80% of China's hyaluronic acid products are foreign brands. Domestic brands are still at the relative bottom of the industrial chain, but the quality of products is not worse than that of foreign countries, or the problem of consumer concept, domestic in the marketing end, brand end and other aspects to do better.

1Chief Chen Yang, Chief Financial Officer of Pharmaceutical Network

"The Internet medical track is a state of competition"

Under the whole epidemic, the development of both online chain pharmacies and offline pharmaceutical e-commerce is very good. Moreover, the online and offline linkage has been enhanced, and the chains of the head and the top 100 chains have e-commerce departments and have launched O2O. The Internet medical track is a state of competition, there is competition and cooperation, everything is around how to better serve consumers.

1 Pharmaceutical Network has done a lot of scientific and technological empowerment work for pharmaceutical companies, and we have some targeted solutions in helping pharmaceutical companies to do digital upgrades, in research and development, marketing, and CRM.

Pharmacies are characterized by being very fragmented, and for them, digital transformation is very difficult. We help them become more efficient through SaaS tools. For example, a small chain of pharmacies may take a week to complete the purchase of the month, because he needs to understand the category and price with different wholesalers. However, after cooperating with us, through information tools such as intelligent procurement systems, you can complete the entire month's procurement in dozens of minutes, which is very efficient.

We would like to see a trend of prescription outflows, more to the out-of-hospital markets we cover, but not immediately to the retail market is still closely watching. Many new special drugs will first circulate to the hospital pharmacy, because such drugs have higher requirements for professional services. In addition, retail pharmacies are also constantly upgrading, and the next offline retail space will become more and more expensive, so it must improve the efficiency, in addition to drugs, medical aesthetic products may also enter the pharmacy end. We are generally optimistic about the opportunity of prescription outflow, but we will pay close attention to what kind of outflow will be carried out to the out-of-hospital market.